Paper Details

  1. Home
  2. Paper Details

Evidence-based recommendations for induction and maintenance treatment of newly diagnosed transplant-ineligible multiple myeloma patients.

Author: AliSundas, AnwerFaiz, AshrafSara, EhsanHamid, KhalidFarhan, KhanIsrar, KhanSana Irfan, KhouriJack, MazzoniSandra, NeupaneKarun, RafaeAbdul, SamarasChristy, ValentJason, WahabAhsan

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Maintenance therapy (MT) after initial induction therapy for newly diagnosed, transplant-ineligible multiple myeloma (NDMM) patients is becoming increasingly common. Lenalidomide-based regimens are still the first-line treatment, but bortezomib-based regimens are also becoming popular. MT regimens are typically based on the initial induction regimen and have shown to improve survival rates. The most common side effects of MT include anemia, neutropenia, thrombocytopenia, infections, and peripheral neuropathy. More clinical trials are needed to further evaluate the role of MT for NDMM patients who are ineligible for autologous stem cell transplantation.
Paper Details　
Original Abstract of the Article :
There is increasing evidence regarding the role of various maintenance therapy (MT) strategies after initial induction to treat newly diagnosed transplant-ineligible patients with MM. We reviewed the literature on available regimens for patients with transplant-ineligible newly diagnosed multiple my...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.critrevonc.2022.103744

データ提供：米国国立医学図書館（NLM）

Tackling Transplant-Ineligible Multiple Myeloma: A Desert of Hope

The [treatment of transplant-ineligible multiple myeloma (NDMM)] presents significant challenges. This study examines the evidence-based recommendations for [induction and maintenance treatment] of NDMM. Much like a desert explorer seeking the most effective route to a distant oasis, this research explores the best strategies for managing this challenging disease.

Navigating the Landscape of Multiple Myeloma Treatment

The study reveals that [lenalidomide (R)-based regimens are still the front-line therapy] for NDMM, with increasing use of [bortezomib-based regimens]. The study also highlights the importance of [maintenance therapy (MT)], demonstrating its [survival benefits] compared to patients without MT. This is akin to providing a well-stocked caravan with essential supplies for a long desert journey, ensuring the best possible chance of survival.

Hope for Transplant-Ineligible Multiple Myeloma Patients

The study offers a glimmer of hope for individuals with NDMM, suggesting that [MT strategies can significantly improve outcomes]. This is a crucial finding, particularly for those who are not candidates for [autologous stem cell transplantation]. Much like discovering a hidden oasis in the desert, this research offers a new avenue for managing this challenging disease.

Dr.Camel's Conclusion

This study highlights the importance of maintenance therapy in the treatment of transplant-ineligible multiple myeloma. The findings suggest that MT strategies can significantly improve survival outcomes and offer hope for individuals who are not candidates for autologous stem cell transplantation. This research underscores the need for continued efforts to optimize treatments for this challenging disease.

Date :
  1. Date Completed 2022-07-26
  2. Date Revised 2022-07-26
Further Info :

Pubmed ID

35717005

DOI: Digital Object Identifier

10.1016/j.critrevonc.2022.103744

Related Literature

Article Analysis
・Effects of ixazomib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.